N-803 + cisplatin + pembrolizumab + pemetrexed

This is a **combination therapy** containing four agents: N-803 (an interleukin-15 (IL-15) superagonist immunostimulatory cytokine), cisplatin (a platinum-based chemotherapy), pembrolizumab (a monoclonal antibody checkpoint inhibitor targeting PD-1), and pemetrexed (a folate antimetabolite chemotherapy). - **N-803** is designed to activate and proliferate NK and memory CD8+ T cells, thus potentiating immune-based antitumor responses. - **Cisplatin** binds to and crosslinks DNA, inhibiting DNA replication and leading to apoptosis. It is commonly used in solid tumor chemotherapy regimens. - **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor, blocking its interaction with PD-L1/PD-L2 and thereby enhancing T cell-mediated immune response against tumor cells. - **Pemetrexed** is a multi-targeted antifolate that disrupts folate-dependent metabolic processes essential for cell replication. This combination is being explored mainly for non-small cell lung cancer (NSCLC) and is under investigation in clinical trials.